Table I.
Overview of intensive care unit (ICU) patients (1st January–31st December 2021)
| COVID-19 ICU patients |
General ICU patients |
|||
|---|---|---|---|---|
| Tocilizumab | No tocilizumab | |||
| N | 41 | 33 | 332 | |
| Age (years) | Median | 64 | 64 | 64 |
| Range | 21–77 | 32–81 | 16–88 | |
| Gender | % Male | 63 | 55 | 60 |
| Co-morbidities (%) | Respiratory | 32 | 36 | - |
| Cardiovascular | 42 | 42 | - | |
| Diabetes mellitus | 17 | 39 | - | |
| Renal disease | 2 | 15 | - | |
| Liver disease | 0 | 6 | - | |
| Haem/oncology | 5 | 12 | - | |
| Immunosuppressed | 17 | 18 | - | |
| Obesity | 44 | 21 | - | |
| Length of ICU stay (days) | All patients | |||
| Median | 18 | 9 | 4 | |
| Range | 1–95 | 1–103 | 1–90 | |
| Survivors | ||||
| Median | 21 | 9 | 5 | |
| Range | 3–95 | 2–103 | 1–74 | |
| Length of hospital stay (days) | All patients | |||
| Median | 23 | 23 | 15 | |
| Range | 7–109 | 1–154 | 1–253 | |
| Survivors | ||||
| Median | 45 | 34 | 20 | |
| Range | 9–109 | 6–154 | 1–253 | |
COVID-19, coronavirus disease 2019.